Literature DB >> 21342917

SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus.

J G Hanly1, M B Urowitz, D Jackson, S C Bae, C Gordon, D J Wallace, A Clarke, S Bernatsky, A Vasudevan, D Isenberg, A Rahman, J Sanchez-Guerrero, J Romero-Diaz, J T Merrill, P R Fortin, D D Gladman, I N Bruce, K Steinsson, M Khamashta, G S Alarcón, B Fessler, M Petri, S Manzi, O Nived, G Sturfelt, R Ramsey-Goldman, M A Dooley, C Aranow, R Van Vollenhoven, M Ramos-Casals, A Zoma, K Kalunian, V Farewell.   

Abstract

OBJECTIVE: To examine change in health-related quality of life in association with clinical outcomes of neuropsychiatric events in systemic lupus erythematosus (SLE).
METHODS: An international study evaluated newly diagnosed SLE patients for neuropsychiatric events attributed to SLE and non-SLE causes. The outcome of events was determined by a physician-completed seven-point scale and compared with patient-completed Short Form 36 (SF-36) health survey questionnaires. Statistical analysis used linear mixed-effects regression models with patient-specific random effects.
RESULTS: 274 patients (92% female; 68% Caucasian), from a cohort of 1400, had one or more neuropsychiatric event in which the interval between assessments was 12.3 ± 2 months. The overall difference in change between visits in mental component summary (MCS) scores of the SF-36 was significant (p<0.0001) following adjustments for gender, ethnicity, centre and previous score. A consistent improvement in neuropsychiatric status (N=295) was associated with an increase in the mean (SD) adjusted MCS score of 3.66 (0.89) in SF-36 scores. Between paired visits when the neuropsychiatric status consistently deteriorated (N=30), the adjusted MCS score decreased by 4.00 (1.96). For the physical component summary scores the corresponding changes were +1.73 (0.71) and -0.62 (1.58) (p<0.05), respectively. Changes in SF-36 subscales were in the same direction (p<0.05; with the exception of role physical). Sensitivity analyses confirmed these findings. Adjustment for age, education, medications, SLE disease activity, organ damage, disease duration, attribution and characteristics of neuropsychiatric events did not substantially alter the results.
CONCLUSION: Changes in SF-36 summary and subscale scores, in particular those related to mental health, are strongly associated with the clinical outcome of neuropsychiatric events in SLE patients.

Entities:  

Mesh:

Year:  2011        PMID: 21342917      PMCID: PMC3795436          DOI: 10.1136/ard.2010.138792

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  30 in total

1.  Systemic Lupus International Collaborating Group--onwards and upwards?

Authors:  D Isenberg; R Ramsey-Goldman
Journal:  Lupus       Date:  2006       Impact factor: 2.911

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.

Authors:  Mikiko Tokunaga; Kazuyoshi Saito; Daisuke Kawabata; Yoshitaka Imura; Takao Fujii; Shingo Nakayamada; Shizuyo Tsujimura; Masao Nawata; Shigeru Iwata; Taeko Azuma; Tsuneyo Mimori; Yoshiya Tanaka
Journal:  Ann Rheum Dis       Date:  2006-11-15       Impact factor: 19.103

4.  Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.

Authors:  John G Hanly; Grace McCurdy; Lisa Fougere; Jo-Anne Douglas; Kara Thompson
Journal:  J Rheumatol       Date:  2004-11       Impact factor: 4.666

5.  Neuropsychiatric syndromes in lupus: prevalence using standardized definitions.

Authors:  R L Brey; S L Holliday; A R Saklad; M G Navarrete; D Hermosillo-Romo; C L Stallworth; C R Valdez; A Escalante; I del Rincón; G Gronseth; C B Rhine; P Padilla; D McGlasson
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

6.  The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus.

Authors:  Wilmer L Sibbitt; John R Brandt; Courtney R Johnson; Marcos E Maldonado; Samir R Patel; Corey C Ford; Arthur D Bankhurst; William M Brooks
Journal:  J Rheumatol       Date:  2002-07       Impact factor: 4.666

Review 7.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03

8.  Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases.

Authors:  V Strand; B Crawford; J Singh; E Choy; J S Smolen; D Khanna
Journal:  Ann Rheum Dis       Date:  2009-12       Impact factor: 19.103

9.  Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies.

Authors:  Vibeke Strand; Bruce Crawford
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2005-06       Impact factor: 2.217

10.  Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study.

Authors:  J G Hanly; M B Urowitz; L Su; J Sanchez-Guerrero; S C Bae; C Gordon; D J Wallace; D Isenberg; G S Alarcón; J T Merrill; A Clarke; S Bernatsky; M A Dooley; P R Fortin; D Gladman; K Steinsson; M Petri; I N Bruce; S Manzi; M Khamashta; A Zoma; J Font; R Van Vollenhoven; C Aranow; E Ginzler; O Nived; G Sturfelt; R Ramsey-Goldman; K Kalunian; J Douglas; K Qiufen Qi; K Thompson; V Farewell
Journal:  Arthritis Rheum       Date:  2008-05-15
View more
  11 in total

1.  Neuropsychiatric Symptoms in Lupus.

Authors:  Maria Gulinello; Jing Wen; Chaim Putterman
Journal:  Psychiatr Ann       Date:  2012-09

Review 2.  Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management.

Authors:  Mariana Postal; Lilian T L Costallat; Simone Appenzeller
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

3.  Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study.

Authors:  John G Hanly; Murray B Urowitz; Li Su; Caroline Gordon; Sang-Cheol Bae; Jorge Sanchez-Guerrero; Juanita Romero-Diaz; Daniel J Wallace; Ann E Clarke; Em Ginzler; Joan T Merrill; David A Isenberg; Anisur Rahman; M Petri; Paul R Fortin; Dd Gladman; Ian N Bruce; Kristjan Steinsson; Ma Dooley; Munther A Khamashta; Graciela S Alarcón; Barri J Fessler; Rosalind Ramsey-Goldman; Susan Manzi; Asad A Zoma; Gunnar K Sturfelt; Ola Nived; Cynthia Aranow; Meggan Mackay; Manuel Ramos-Casals; Rf van Vollenhoven; Kenneth C Kalunian; Guillermo Ruiz-Irastorza; Sam Lim; Diane L Kamen; Christine A Peschken; Murat Inanc; Chris Theriault; Kara Thompson; Vernon Farewell
Journal:  Ann Rheum Dis       Date:  2012-04-04       Impact factor: 19.103

4.  Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Authors:  John G Hanly; Qiuju Li; Li Su; Murray B Urowitz; Caroline Gordon; Sang-Cheol Bae; Juanita Romero-Diaz; Jorge Sanchez-Guerrero; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; David A Isenberg; Anisur Rahman; Joan T Merrill; Paul R Fortin; Dafna D Gladman; Ian N Bruce; Michelle Petri; Ellen M Ginzler; M A Dooley; Kristjan Steinsson; Rosalind Ramsey-Goldman; Asad A Zoma; Susan Manzi; Ola Nived; Andreas Jonsen; Munther A Khamashta; Graciela S Alarcón; Elisabet Svenungsson; Ronald F van Vollenhoven; Cynthia Aranow; Meggan Mackay; Guillermo Ruiz-Irastorza; Manuel Ramos-Casals; S Sam Lim; Murat Inanc; Kenneth C Kalunian; Soren Jacobsen; Christine A Peschken; Diane L Kamen; Anca Askanase; Chris Theriault; Vernon Farewell
Journal:  Arthritis Rheumatol       Date:  2019-11-28       Impact factor: 10.995

5.  Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Authors:  John G Hanly; Qiuju Li; Li Su; Murray B Urowitz; Caroline Gordon; Sang-Cheol Bae; Juanita Romero-Diaz; Jorge Sanchez-Guerrero; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; David A Isenberg; Anisur Rahman; Joan T Merrill; Paul Fortin; Dafna D Gladman; Ian N Bruce; Michelle Petri; Ellen M Ginzler; M A Dooley; Kristjan Steinsson; Rosalind Ramsey-Goldman; Asad A Zoma; Susan Manzi; Ola Nived; Andreas Jonsen; Munther A Khamashta; Graciela S Alarcón; Winn Chatham; Ronald F van Vollenhoven; Cynthia Aranow; Meggan Mackay; Guillermo Ruiz-Irastorza; Manuel Ramos-Casals; S Sam Lim; Murat Inanc; Kenneth C Kalunian; Soren Jacobsen; Christine A Peschken; Diane L Kamen; Anca Askanase; Chris Theriault; Vernon Farewell
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-09-01       Impact factor: 4.794

6.  Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Authors:  John G Hanly; Li Su; Murray B Urowitz; Juanita Romero-Diaz; Caroline Gordon; Sang-Cheol Bae; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; Joan T Merrill; David A Isenberg; Anisur Rahman; Ellen M Ginzler; Michelle Petri; Ian N Bruce; M A Dooley; Paul Fortin; Dafna D Gladman; Jorge Sanchez-Guerrero; Kristjan Steinsson; Rosalind Ramsey-Goldman; Munther A Khamashta; Cynthia Aranow; Graciela S Alarcón; Barri J Fessler; Susan Manzi; Ola Nived; Gunnar K Sturfelt; Asad A Zoma; Ronald F van Vollenhoven; Manuel Ramos-Casals; Guillermo Ruiz-Irastorza; S Sam Lim; Kenneth C Kalunian; Murat Inanc; Diane L Kamen; Christine A Peschken; Soren Jacobsen; Anca Askanase; Chris Theriault; Kara Thompson; Vernon Farewell
Journal:  Arthritis Rheumatol       Date:  2015-07       Impact factor: 10.995

7.  Neuropsychiatric symptoms in systemic lupus erythematosus: impact on quality of life.

Authors:  R C Monahan; L J J Beaart-van de Voorde; G M Steup-Beekman; C Magro-Checa; T W J Huizinga; J Hoekman; A A Kaptein
Journal:  Lupus       Date:  2017-02-22       Impact factor: 2.911

8.  Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review.

Authors:  Vibeke Strand; Lee S Simon; Alexa Simon Meara; Zahi Touma
Journal:  Lupus Sci Med       Date:  2020-06

9.  Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort.

Authors:  John G Hanly; Caroline Gordon; Sang-Cheol Bae; Juanita Romero-Diaz; Jorge Sanchez-Guerrero; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; David A Isenberg; Anisur Rahman; Joan T Merrill; Paul R Fortin; Dafna D Gladman; Murray B Urowitz; Ian N Bruce; Michelle Petri; Ellen M Ginzler; M A Dooley; Rosalind Ramsey-Goldman; Susan Manzi; Andreas Jonsen; Graciela S Alarcón; Ronald F van Vollenhoven; Cynthia Aranow; Meggan Mackay; Guillermo Ruiz-Irastorza; S Sam Lim; Murat Inanc; Kenneth C Kalunian; Soren Jacobsen; Christine A Peschken; Diane L Kamen; Anca Askanase; Vernon Farewell
Journal:  Arthritis Rheumatol       Date:  2021-10-29       Impact factor: 15.483

10.  Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Authors:  John G Hanly; Qiuju Li; Li Su; Murray B Urowitz; Caroline Gordon; Sang-Cheol Bae; Juanita Romero-Diaz; Jorge Sanchez-Guerrero; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; David A Isenberg; Anisur Rahman; Joan T Merrill; Paul R Fortin; Dafna D Gladman; Ian N Bruce; Michelle Petri; Ellen M Ginzler; M A Dooley; Kristjan Steinsson; Rosalind Ramsey-Goldman; Asad A Zoma; Susan Manzi; Ola Nived; Andreas Jonsen; Munther A Khamashta; Graciela S Alarcón; Ronald F van Vollenhoven; Cynthia Aranow; Meggan Mackay; Guillermo Ruiz-Irastorza; Manuel Ramos-Casals; S Sam Lim; Murat Inanc; Kenneth C Kalunian; Soren Jacobsen; Christine A Peschken; Diane L Kamen; Anca Askanase; Chris Theriault; Vernon Farewell
Journal:  Arthritis Rheumatol       Date:  2019-01-18       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.